System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Studies

Interventional Not yet recruiting

NCT07317180 on ClinicalTrials.gov

Meta Glasses for Low Vision

Official title: The Use of Meta AI Glasses With Be My Eyes Network to Improve Mobility in Patients With Low Vision

  • Sponsor: London Health Sciences Centre
  • Enrollment: 50 (Estimated)
  • Study start: 2026-02-01 (Estimated)
  • Primary completion: 2027-02-01 (Estimated)
  • Study completion: 2027-07-01 (Estimated)
  • Allocation: Randomized
  • InterventionModel: Single Group
  • Masking: Double (Investigator, Outcomes Assessor)
  • PrimaryPurpose: Supportive Care

Brief Summary

Visual impairment, particularly from glaucoma and retinal dystrophies, significantly hinders mobility and increases the risk of falls, leading to decreased independence and mental health challenges. Current low-vision assistive technologies primarily focus on near-task magnification for reading, leaving a critical gap in tools designed to assist with real-world navigation and peripheral vision loss. To address this, the proposed research evaluates Meta AI glasses, which offer real-time scene narration and object recognition, integrated with the Be My Eyes network. The study hypothesizes that this wearable AI technology will improve ambulation, orientation, and overall quality of life for patients, providing a functional solution for mobility that traditional devices lack.

Conditions

  • Irreversible Vision Loss

Intervention / Treatment

  • Other: Meta AI Glasses
  • Other: Control

Primary Outcome Measures

  • patient-reported vision-targeted quality of life (4 weeks)
    The primary outcome will be change in patient-reported vision-targeted quality of life, measured using the National Eye Institute Visual Function Questionnaire - 25 item (NEI VFQ-25).